Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant MEDI4736 vs placebo after neoadjuvant chemoradiotherapy and complete resection for esophageal squamous cell carcinoma
KCT0004987Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2016
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by AstraZeneca. Started Mar 2016; status: completed.
02
Drugs
durvalumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on KCT0004987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004987.